Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland

Journal of Affective Disorders

Volumn 120, Issue 1-3, 2010, Pages 94-104

  Benedict, Ágnes ^a   Arellano, Jorge ^b   De Cock, Erwin ^a   Baird, Jessamy ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Eli Lilly   (United Kingdom)

Author keywords

Antidepressant medication; Cost utility analysis; Major depressive disorder

Indexed keywords

CITALOPRAM; DULOXETINE; FLUOXETINE; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENERAL PRACTITIONER; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHIATRIST; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; HEALTH CARE COSTS; HUMANS; MIANSERIN; PREVALENCE; QUALITY OF LIFE; RECURRENCE; REMISSION INDUCTION; SCOTLAND; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TIME FACTORS;

EID: 71849092827     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2009.04.017     Document Type: Article

References (35)

1. Baca E., and Rubio-Terrés C. Análysis farmacoeconómico del tratamiento del trastorno depresivo major con venlafaxina retard o duloxetina. Pharamcoecon.-Span. Res. Artic. 3 3 (2006) 89-98
2. Barrett B., Byford S., and Knapp M. Evidence of cost-effective treatments for depression: a systematic review. J. Affect. Disord. 84 (2005) 1-13
3. Briggs A., and Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 7 (1998) 723-740
4. Detke M.J., Lu Y., Goldstein D.J., Hayes J.R., and Demitrack M.A. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry 63 4 (2002) 308-315
5. Detke M.J., Lu Y., Goldstein D.J., McNamara R.K., and Demitrack M.A. Duloxetine 60 mg daily dosing versus placebo in the acute treatment of major depression. J. Psychiatr. Res. 36 6 (2002) 383-390
6. Detke M.J., Wiltse C.G., Mallinckrodt C.H., McNamara R.K., Demitrack M.A., and Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Neuropsychopharmacol. 14 6 (2004) 457-470
7. Drummond, M., McGuire, A., 2001. A. Economic evaluation in health care: merging theory with practice. Oxford University Press/Office of Health Economics.
8. Goldstein, D.J., Lu, Y., Detke, M.J., Wiltse, C., Mallinckrodt, C., Demitrack, M.A., 2004. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J. Clin. Psychopharmacol. 24, 389-399.
9. Hudson J.I., Perahia D.G., Gilaberte I., Wang F., Watkin J.G., and Detke M.J. Duloxetine in the treatment of major depressive disorder: an open-label study. BMC Psychiatr. 28;7 1 (2007) 43
10. Kennedy N., Abbott R., and Paykel E.S. Remission and recurrence of depression in the maintenance era: long-term outcome in a Cambridge cohort. Psychol. Med. 33 5 (2003) 827-838
11. Kroenke K., West S.L., Swindle R., Gilsenan A., Eckert G.J., Dolor R., Stang P., Zhou X.H., Hays R., and Weinberger M. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 286 (2001) 2947-2955
12. Kruijshaar M.E., Hoeymans N., Bijl R.V., Spijker J., and Essink-Bot M.L. Levels of disability in major depression: findings from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). J. Affect. Disord. 77 (2003) 53-64
13. Llorca P.M., and Fernandez J.L. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int. J. Clin. Pract. 61 4 (2007) 702-710 Apr
14. Malone D.C. A budget-impact and cost-effectiveness model for second-line treatment of major depression. J. Manag. Care Pharm. 13 6 Suppl A (2007) S8-S18 Jul
15. Munoz, R.A., 2002. American psychiatric association practice guidelines for the treatment of psychiatric disorders: Compendium 2000. Am J Psychiatry 159, 1066.
16. Nemeroff C.B., and Owens M.J. Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectr. 9 6 Suppl 4 (2004) 23-31
17. NICE. National Institute of Clinical Excellence Guide to the Methods of Technology Appraisal, April 2004 (Ref N0515), paragraphs 6.2.6.10-11.
18. The new NICE version is from June 2008. accessed may 2009: http://www.nice.org.uk/aboutnice/howwework/devnicetech/technologyapprais alprocessguides/guidetothemethodsoftechnologyappraisal.jsp?domedia=1 &mid=B52851A3-19B9-E0B5-D48284D172BD8459.
19. National Institute of Clinical Excellence, 2007. Depression: management of depression in primary and secondary care - NICE guidance. Clinical Guideline 23. Issued in 2004, amended in April 2007.
20. Office for National Statistics (ONS), 2000. Key Health Statistics from General Practice 1998. Table 5A7: Prevalence of treated depression per 1000 patients, by age, sex and calendar year: 1994-98.
21. Paykel E.S., Brugha T., and Fryers T. Size and burden of depressive disorders in Europe. Eur. Neuropsychopharmacol. 15 4 (2005) 411-423 Aug
22. Perahia, D.G., Kajdasz, D.K., Royer, M.G., Walker, D.J., Raskin, J., 2006. Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics. Int. Clin. Psychopharmacol. 21, 285-295.
23. Perahia D.G., Pritchett Y.L., Kajdasz D.K., Bauer M., Jain R., Russell J.M., Walker D.J., Spencer K.A., Froud D.M., Raskin J., and Thase M.E. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J. Psychiatr. Res. 42 (2008) 22-34
24. Revicki D.A., and Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J. Affect. Disord. 48 (1998) 25-36
25. Sorensen J., Stage K.B., Damsbo N., Le Lay A., and Hemels M.E. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord. J. Psychiatry 61 2 (2007) 100-108
26. Stahl S., Zivkov M., Reimitz P.E., Panagides J., and Hoff W. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr. Scand., Suppl. 391 (1997) 22-30
27. Stinnett A.A., and Paltiel A.D. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med. Decis. Mak. 17 (1997) 483-489
28. Swindle, R.W., Mallinckrodt, C.H., et al. Efficacy of duloxetine treatment: analysis of pooled data from six placebo- and SSRI- controlled clinical trial. Poster presented at ECNP 2004.
29. Thase, M., et al., 2003. Remission in placebo-controlled trials of duloxetine with an SSRI comparator. American Psychiatric Association conference, 2003.
30. Thase M.E., Tran P.V., Wiltse C., Pangallo B.A., Mallinckrodt C., and Detke M.J. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J. Clin. Psychopharmacol. 25 2 (2005) 132-140 Apr
31. Thase M.E., Pritchett Y.L., Ossanna M.J., Swindle R.W., Xu J., and Detke M.J. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J. Clin. Psychopharmacol. 27 6 (2007) 672-676 Dec
32. The ESEMeD/MHEDEA 2000 Investigators*. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr. Scand., Suppl. 420 (2004) 21-27
33. Thomas C.M., and Morris S. Cost of depression among adults in England in 2000. Br. J. Psychiatry 183 (2003) 514-519 Dec
34. van Baardewijk M., Vis P.M., and Einarson T.R. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder. Curr. Med. Res. Opin. 21 8 (2005) 1271-1279 Aug
35. World Health Organization, 2001. The world health report 2001 - mental health: new understanding, new hope.